The effect of different doses of remifentanil on sedation and stress response in patients undergoing percutaneous kyphoplasty

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400092178

Enrollment

Unknown

Registered

2024-11-12

Start date

2024-11-14

Completion date

Unknown

Last updated

2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vertebral compressibility fracture

Interventions

R1:low dosage of Remazlam

R2:high dosage of Remazlam

Eligibility

Sex/Gender

All

Age

55 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Preoperative diagnosis of Vertebral compressibility fracture; 2.ASA I-III; 3.aged 55-90; 4.Normal cognitive function, able to cooperate with treatment;

Exclusion criteria

Exclusion criteria: 1.Combined coagulation dysfunction; 2.severe organ diseases such as liver, kidney, brain, etc; 3.Related drug allergy history; 4.severe cardiovascular and cerebrovascular diseases; 5.Long term use of analgesic drugs; 6.The patient refused to cooperate with the collaborator;

Design outcomes

Primary

Measure	Time frame
VAS;Ramsay sedation scoring;	—

Secondary

Measure	Time frame
satisfaction;Adverse reactions;Serum C-reactive protein;Interleukin-6;	—

Countries

China

Contacts

Public ContactZhang Ye

Ningbo Medical Centre Lihuili Hospital

shi5299@126.com+86 574 55835827

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026